Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer

Anticancer Research

Volumn 19, Issue 3 B, 1999, Pages 2365-2367

  Moser, Patrizia L ^b   Hefler, Lukas ^b   Tempfer, Clemens ^b   Neunteufel, Walter ^b   Kieback, Dirk G ^b   Gitsch, Gerald ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NONE

Author keywords

Endometrial cancer; Immunohistochemistry; Metalloproteinases

Indexed keywords

COLLAGENASE; GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; ENDOMETRIUM CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS;

AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; COLLAGENASES; ENDOMETRIAL NEOPLASMS; FEMALE; GELATINASES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODE EXCISION; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; METALLOENDOPEPTIDASES; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 0032774472     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Gitsch G, Hanzal E, Jensen D, Hacker NF: Endometrial cancer in Premenopausal women 45 years and younger. Obstet Gynecol 85: 504-508, 1995,
2. Kohlberger P, Gitsch G, Loesch A, Tempfer C, Kaider A, Reinthaller A, Kainz C, Breotenecker G: p53 overexpression in early stage endometrial cancer. Gynecol Oncol 62: 213-217, 1996.
3. Gitsch G, Friedlander M, Wain GV, Hacker NF: Uterine papillary serous carcinoma. Cancer 75: 2239-2243, 1995.
4. Woessner FJ: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5: 2145-2154, 1991.
5. Mignatti P, Rifkin D: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73: 161-195, 1993.
6. Fishman DA, Bafetti LM, Sharon Stack M: Membrane- type matrix. Metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 16: 150-159, 1996.
7. Autio-Harmainen H, Karttunen T, Hurskainen T, Hoyhta M, Kauppila A, Tryggvason K: Expression of 72 kDa type IV collagenase (gelatinase A) in benigne and malignant ovarian tumors. Lab Invest 69: 312-321, 1993.
8. Naylor MS, Stamp GW, Davies BD, Balkwill FR: Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer, 58: 50-56, 1994.
9. Afzal S, Lalani EN, Foulkes WD, Boyc'e B, Tickle S, Cardillo MR, Baker T, Pign'atelli M, Stamp GWH: Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest 74: 406-421, 1996.
10. Davidson B, Goldberg 1, Gotlieb WH, Ben-Baruch G, Kopolovic J: Expression of matrix proteins in uterine cervical neoplasia using immunohistochemistry. Europ J Obst Gyn Reprod Biol 76: 109-114, 1998.
11. Mignatti P, Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73: 161-195, 1993.
12. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasinogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-166, 1985.
13. Sharon Stack M, Ellerbroek SM, Fishman DA: The role of proteolytic enzymes in pathology of epithelial ovarian carcinoma. Int J Oncol 12: 569-576, 1998.
14. Hawkins MJ: Clinical trials of antiangiogenetic agents. Curr Opin Oncol 7: 90-3, 1995.
15. Obermair A., Wanner C, Bilgi S, Speiser P, Kaider A, Reinthaller A, Leodolter S, Gitsch G: Tumor angiogenesis in stage IB cervical cancer: Correlation of microvessel density with survival. Am J Obstet Gynecol 178: 314-9, 1998.